Publicacións en colaboración con investigadores/as de Hospital de Santa Maria (21)

2016

  1. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  3. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

    PLoS ONE, Vol. 9, Núm. 1

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

  2. Hepatitis delta in HIV-infected individuals in Europe

    AIDS, Vol. 25, Núm. 16, pp. 1987-1992

  3. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naïve HIV-2-infected patients: The ACHIEV2E collaboration study group

    Clinical Infectious Diseases, Vol. 52, Núm. 10, pp. 1257-1266

  4. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial

    Antiviral Therapy, Vol. 16, Núm. 3, pp. 339-348

2010

  1. Dialysis and renal transplantation in HIV-infected patients: A European survey

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 5, pp. 582-589

  2. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 548-555

2009

  1. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

2008

  1. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

    AIDS, Vol. 22, Núm. 3, pp. 367-376

  2. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 3, pp. 694-698

2002

  1. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts

    Journal of Infectious Diseases, Vol. 186, Núm. 2, pp. 189-197

2000

  1. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

    Journal of Clinical Microbiology, Vol. 38, Núm. 4, pp. 1370-1374